George Fountzilas

Summary

Affiliation: Aristotle University of Thessaloniki
Country: Greece

Publications

  1. doi request reprint A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer
    George Fountzilas
    Department of Medical Oncology, Papageorgiou Hospital, Aristotle University of Thessaloniki School of Medicine, 564 03, Thessaloniki, Macedonia, Greece
    Cancer Chemother Pharmacol 65:649-60. 2010
  2. pmc Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trial
    George Fountzilas
    Department of Medical Oncology, Papageorgiou Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece
    PLoS ONE 8:e69256. 2013
  3. pmc Molecular predictors of response to tyrosine kinase inhibitors in patients with Non-Small-Cell Lung Cancer
    Samuel Murray
    BioMarker Solutions Ltd, London, UK
    J Exp Clin Cancer Res 31:77. 2012
  4. pmc XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis
    Dimitrios Pectasides
    Oncology Section, Second Department of Internal Medicine, Hippokration Hospital, University of Athens School of Medicine, Athens, Greece
    BMC Cancer 12:271. 2012
  5. pmc Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperat
    George Fountzilas
    Department of Medical Oncology, Papageorgiou Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece
    BMC Cancer 13:163. 2013
  6. pmc Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel
    George Fountzilas
    Department of Medical Oncology, Papageorgiou Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece
    PLoS ONE 7:e37946. 2012
  7. pmc Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab
    George Fountzilas
    Department of Medical Oncology, Papageorgiou Hospital, Aristotle University of Thessaloniki School of Medicine, 564 03, Thessaloniki, Macedonia, Greece
    J Transl Med 10:212. 2012
  8. doi request reprint Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: a randomized phase II study conducted by the Hellenic Cooperative Oncology Group (HeC
    G Fountzilas
    Department ofMedical Oncology Papageorgiou Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece
    Ann Oncol 23:427-35. 2012
  9. pmc HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy
    George Fountzilas
    Department of Medical Oncology, Papageorgiou Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece
    J Transl Med 10:10. 2012
  10. pmc A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: a Hellenic Cooperative Oncology Group study
    Christos A Papadimitriou
    Department of Clinical Therapeutics, Alexandra Hospital, University of Athens School of Medicine, Athens, Greece
    BMC Med 9:10. 2011

Collaborators

Detail Information

Publications61

  1. doi request reprint A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer
    George Fountzilas
    Department of Medical Oncology, Papageorgiou Hospital, Aristotle University of Thessaloniki School of Medicine, 564 03, Thessaloniki, Macedonia, Greece
    Cancer Chemother Pharmacol 65:649-60. 2010
    ..Angiogenesis is an important biological process in SCCHN. We, therefore, evaluated the activity and safety of sunitinib, an oral tyrosine kinase inhibitor that targets multiple receptors, in patients with RM-SCCHN...
  2. pmc Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trial
    George Fountzilas
    Department of Medical Oncology, Papageorgiou Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece
    PLoS ONE 8:e69256. 2013
    ..A number of markers identified in the present trial appear to deserve further evaluation for their prognostic and/or predictive value in larger multi-arm studies...
  3. pmc Molecular predictors of response to tyrosine kinase inhibitors in patients with Non-Small-Cell Lung Cancer
    Samuel Murray
    BioMarker Solutions Ltd, London, UK
    J Exp Clin Cancer Res 31:77. 2012
    ..In this study, we aimed to characterize several molecular events involved in potential resistance mechanisms to anti-EGFR treatment and correlate our findings with clinical outcome...
  4. pmc XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis
    Dimitrios Pectasides
    Oncology Section, Second Department of Internal Medicine, Hippokration Hospital, University of Athens School of Medicine, Athens, Greece
    BMC Cancer 12:271. 2012
    ..The aim was to compare two standard chemotherapy regimens combined with bevacizumab as first-line treatment in patients with metastatic colorectal cancer...
  5. pmc Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperat
    George Fountzilas
    Department of Medical Oncology, Papageorgiou Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece
    BMC Cancer 13:163. 2013
    ..Limited information exists on the relationship of HER2/TOP2A gene status in the presence of centromere 17 (CEP17) gain with outcome of patients treated with anthracycline-containing adjuvant chemotherapy...
  6. pmc Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel
    George Fountzilas
    Department of Medical Oncology, Papageorgiou Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece
    PLoS ONE 7:e37946. 2012
    ....
  7. pmc Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab
    George Fountzilas
    Department of Medical Oncology, Papageorgiou Hospital, Aristotle University of Thessaloniki School of Medicine, 564 03, Thessaloniki, Macedonia, Greece
    J Transl Med 10:212. 2012
    ..The aim of this study was to investigate the prognostic role of topoisomerase II alpha gene (TOP2A) amplification and protein (TopoIIa) expression in patients treated with trastuzumab-containing regimens...
  8. doi request reprint Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: a randomized phase II study conducted by the Hellenic Cooperative Oncology Group (HeC
    G Fountzilas
    Department ofMedical Oncology Papageorgiou Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece
    Ann Oncol 23:427-35. 2012
    ..The role of induction chemotherapy (IC) when followed by CCRT in improving locoregional control remains controversial...
  9. pmc HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy
    George Fountzilas
    Department of Medical Oncology, Papageorgiou Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece
    J Transl Med 10:10. 2012
    ..The aim of this study was to comprehensively evaluate the prognostic/predictive significance of the above parameters in early, high-risk breast cancer patients treated with epirubicin-based, dose-dense sequential adjuvant chemotherapy...
  10. pmc A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: a Hellenic Cooperative Oncology Group study
    Christos A Papadimitriou
    Department of Clinical Therapeutics, Alexandra Hospital, University of Athens School of Medicine, Athens, Greece
    BMC Med 9:10. 2011
    ..In this multicenter adjuvant phase III trial, we evaluated the addition of irinotecan to weekly 5FU plus LV in patients with stage II or III colon cancer...
  11. pmc Screening of the DNA mismatch repair genes MLH1, MSH2 and MSH6 in a Greek cohort of Lynch syndrome suspected families
    Georgia Thodi
    Molecular Diagnostics Laboratory, I R RP, National Center for Scientific Research Demokritos, Athens, Greece
    BMC Cancer 10:544. 2010
    ....
  12. pmc Mutational spectrum of APC and genotype-phenotype correlations in Greek FAP patients
    Florentia Fostira
    Molecular Diagnostics Laboratory, I R RP, National Center of Scientific Research Demokritos, Athens, Greece
    BMC Cancer 10:389. 2010
    ..Additionally, all available published mutations were considered in order to define the APC mutation spectrum in Greece...
  13. ncbi request reprint Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluation
    George Fountzilas
    Department of Medical Oncology, Papageorgiou Hospital, Ring Road, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece
    Anticancer Res 31:3007-18. 2011
    ..However predictive or prognostic biological markers that identify the appropriate target population, thus improving the cost-effectiveness ratio of this treatment, are still needed...
  14. pmc Expression of DNA repair and replication genes in non-small cell lung cancer (NSCLC): a role for thymidylate synthetase (TYMS)
    Vassiliki Kotoula
    Department of Pathology, Aristotle University of Thessaloniki School of Medicine, Greece
    BMC Cancer 12:342. 2012
    ..The aim of this study was to determine the prognostic/predictive impact of B, E, R, T in routinely-treated NSCLC patients by taking into account the expression of these genes in the normal lung parenchyma...
  15. ncbi request reprint Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF, and weekly docetaxel is feasible and safe in patients with operable breast cancer
    George Fountzilas
    Department of Medical Oncology, Papageorgiou Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece
    Med Oncol 23:479-88. 2006
    ..Infection developed in nine patients. Two cases of febrile neutropenia were reported. The E-CMF-doc regimen, as used in this study, is feasible and well tolerated. Its impact on survival should be evaluated in phase III trials...
  16. pmc Volumetric and MGMT parameters in glioblastoma patients: survival analysis
    Georgios Iliadis
    Department of Radiation Oncology, Papageorgiou Hospital, Thessaloniki, Greece
    BMC Cancer 12:3. 2012
    ..In addition, MGMT (O6-methylguanine methyltransferase) related parameters were compared with those of volumetry in order to observe possible relevance of this molecule in tumor development...
  17. ncbi request reprint Induction chemotherapy with docetaxel and cisplatin followed by concomitant chemoradiotherapy in patients with inoperable non-nasopharyngeal carcinoma of the head and neck
    George Fountzilas
    Department of Medical Oncology, Papageorgiou Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece
    Anticancer Res 29:529-38. 2009
    ..Induction chemotherapy (IC) followed by concomitant chemoradiotherapy (CCRT) has the potential of being an ideal multi-modality approach for improving the prognosis of patients with squamous cell carcinoma of the head and neck (SSCHN)...
  18. pmc Identification and validation of a multigene predictor of recurrence in primary laryngeal cancer
    Elena Fountzilas
    Department of Medical Oncology, Papageorgiou Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece
    PLoS ONE 8:e70429. 2013
    ..This study attempts to identify and independently validate gene expression models, prognostic of disease-free survival (DFS) in operable laryngeal cancer...
  19. doi request reprint Prognostic utility of β-tubulin isotype III and correlations with other molecular and clinicopathological variables in patients with early breast cancer: a translational Hellenic Cooperative Oncology Group (HeCOG) study
    George Pentheroudakis
    Department of Medical Oncology, Ioannina University Hospital, Niarxou Avenue, 45500 Ioannina, Greece
    Breast Cancer Res Treat 127:179-93. 2011
    ..96 for OS, p = 0.46 for DFS). Transcriptional activity of β-tubulin isotype III in early breast cancer is an adverse prognostic factor, though not a predictive one for taxane efficacy...
  20. pmc Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes
    George Pentheroudakis
    Department of Medical Oncology, Ioannina University Hospital, Ioannina, Greece
    BMC Cancer 13:49. 2013
    ..We studied EGFR-axis messenger RNA (mRNA) expression and RAS, RAF, PIK3CA mutations in order to identify additional biomarkers of cetuximab efficacy...
  21. ncbi request reprint Evaluation of the prognostic role of a panel of biomarkers in stage IB-IIIA non-small cell lung cancer patients
    Eleni Timotheadou
    Department of Medical Oncology, Papageorgiou General Hospital, Aristotle University of Thessaloniki School of Medicine, Greece
    Anticancer Res 27:4481-9. 2007
    ..Identification of molecular prognostic and predictive markers remains under investigation with results that are often conflicting...
  22. ncbi request reprint Paclitaxel, cisplatin, leucovorin, and continuous infusion fluorouracil followed by concomitant chemoradiotherapy for locally advanced squamous cell carcinoma of the head and neck: a Hellenic Cooperative Oncology Group Phase II Study
    George Fountzilas
    Department of Medical Oncology, Papageorgiou General Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece
    Med Oncol 22:269-79. 2005
    ..CCRT should remain standard treatment for patients with LA-HNC. Novel induction combinations, such as that reported in the present study, should be evaluated in combination with CCRT only in the context of clinical trials...
  23. doi request reprint Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: a phase II Study of the Hellenic Cooperative Oncology Group with biomarker evaluation
    George Fountzilas
    Department of Medical Oncology, Papageorgiou Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece
    Cancer Invest 26:784-93. 2008
    ..The 6-month progression-free survival (PFS) was 30%. Median PFS was 4.1 months and median survival 7.3 months with a 1 year survival rate of 27%. The above combination demonstrated promising activity in advanced pancreatic cancer...
  24. doi request reprint The importance of tumor volume in the prognosis of patients with glioblastoma: comparison of computerized volumetry and geometric models
    Georgios Iliadis
    Department of Radiation Oncology, Papageorgiou General Hospital, Thessaloniki, Greece
    Strahlenther Onkol 185:743-50. 2009
    ....
  25. ncbi request reprint Post-operative combined radiation and chemotherapy with temozolomide and irinotecan in patients with high-grade astrocytic tumors. A phase II study with biomarker evaluation
    George Fountzilas
    Department of Medical Oncology, Aristotle University of Thessaloniki, Thessaloniki, Greece
    Anticancer Res 26:4675-86. 2006
    ..Clinical studies have shown that temozolomide (TMZ) and irinotecan demonstrate activity in high grade astrocytic tumors (HGAT). However, the optimal schedule of administration is unknown...
  26. doi request reprint A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas
    Vasilios Karavasilis
    Department of Medical Oncology, Papageorgiou General Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece
    J Neurol 260:1469-80. 2013
    ..Combination of TMZ and LP is feasible with manageable toxicity. The activity of this combination in patients with recurrent glioblastoma multiforme is further investigated in a recently initiated phase II trial...
  27. pmc Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy
    Ioannis Kostopoulos
    Department of Medical Oncology Papageorgiou Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece
    BMC Cancer 9:339. 2009
    ..We aimed to study the expression of TS and Topo I in patients with resected CRC who received adjuvant chemotherapy and correlated it with clinical outcome...
  28. doi request reprint Global microRNA profiling in favorable prognosis subgroups of cancer of unknown primary (CUP) demonstrates no significant expression differences with metastases of matched known primary tumors
    George Pentheroudakis
    Department of Medical Oncology, Medical School, University of Ioannina, Niarxou Avenue, 45500 Ioannina, Greece
    Clin Exp Metastasis 30:431-9. 2013
    ..0- and 1.4-fold respectively. Six miRs, which belong to the 17-92 oncocluster showed a trend of upregulation in Breast CUP versus Breast KPM cases. A CUP signature remains elusive...
  29. doi request reprint Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial
    George Pentheroudakis
    Department of Medical Oncology, Ioannina University Hospital, Ioannina, Greece
    Breast Cancer Res Treat 116:131-43. 2009
    ..We sought to study the predictive significance and correlations of transcriptional profiling of the ER, PgR and microtubule-associated protein Tau (MAP-Tau) genes in early breast cancer...
  30. doi request reprint Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors
    George Pentheroudakis
    Department of Medical Oncology, Ioannina University Hospital, Ioannina, Greece
    Crit Rev Oncol Hematol 66:237-47. 2008
    ..We sought to present epidemiology, management and outcome data on fit elderly patients with common metastatic cancers and to identify predictors of clinical benefit from palliative chemotherapy...
  31. pmc Sample parameters affecting the clinical relevance of RNA biomarkers in translational breast cancer research
    Vassiliki Kotoula
    Department of Pathology, Aristotle University of Thessaloniki School of Medicine, University Campus, 54006 Thessaloniki, Greece
    Virchows Arch 462:141-54. 2013
    ..These data will facilitate the design of translational studies involving FFPE sample series...
  32. ncbi request reprint Induction chemotherapy with cisplatin, epirubicin, and paclitaxel (CEP), followed by concomitant radiotherapy and weekly paclitaxel for the management of locally advanced nasopharyngeal carcinoma. A Hellenic Cooperative Oncology Group phase II study
    George Fountzilas
    AHEPA Hospital, Aristotle, University of Thessaloniki, Thessaloniki, Greece
    Strahlenther Onkol 181:223-30. 2005
    ..Clinical research on the treatment of nasopharyngeal cancer (NPC) has been focused primarily on the reduction of incidence of the development of distant metastases as well as the improvement of locoregional control...
  33. doi request reprint Liver metastases from cancer of unknown primary (CUPL): a retrospective analysis of presentation, management and prognosis in 49 patients and systematic review of the literature
    George Lazaridis
    Department of Medical Oncology, Ioannina University Hospital, Niarxou Avenue, 45500 Ioannina, Greece
    Cancer Treat Rev 34:693-700. 2008
    ..Patients with liver metastases from cancer of unknown primary (CUPL) have a dismal prognosis. We retrospectively analysed their management and outcome and performed a systematic review of CUPL series published in the literature...
  34. doi request reprint Phase I trial of weekly irinotecan and paclitaxel combined with carboplatin in patients with advanced cancer: a Hellenic Cooperative Oncology Group Study
    Evangelos Briasoulis
    Department of Medical Oncology, Ioannina University Hospital, Greece
    Anticancer Drugs 21:785-9. 2010
    ..At the recommended doses this is a well-tolerated regimen with noticeable antitumor activity and warrants further investigation in phase II studies...
  35. doi request reprint A study of gene expression markers for predictive significance for bevacizumab benefit in patients with metastatic colon cancer: a translational research study of the Hellenic Cooperative Oncology Group (HeCOG)
    George Pentheroudakis
    Department of Medical Oncology, Ioannina University Hospital, Ioannina, Greece
    BMC Cancer 14:111. 2014
    ..However, tumor biomarkers identifying the molecular tumor subsets most amenable to angiogenesis modulation are lacking...
  36. pmc Novel microRNA-based assay demonstrates 92% agreement with diagnosis based on clinicopathologic and management data in a cohort of patients with carcinoma of unknown primary
    George Pentheroudakis
    Department of Medical Oncology, Medical School, University of Ioannina, Ioannina, Greece
    Mol Cancer 12:57. 2013
    ..MicroRNAs are a family of non-coding, regulatory RNA molecules that are tissue-specific, with a great potential to be excellent biomarkers...
  37. ncbi request reprint Expression of angiogenic markers in the peripheral blood of patients with advanced breast cancer treated with weekly docetaxel
    Ippokratis Korantzis
    Department of Medical Oncology, Papageorgiou Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece
    Anticancer Res 32:4569-80. 2012
    ..The aim of the present study was to investigate the antiangiogenic properties of weekly metronomic docetaxel administration in patients with metastatic breast cancer...
  38. ncbi request reprint The prognostic significance of WNT pathway in surgically-treated colorectal cancer: β-catenin expression predicts for disease-free survival
    Konstantinos Kamposioras
    Department of Medical Oncology, University Hospital of Larissa, 41 110 Larissa, Greece
    Anticancer Res 33:4573-84. 2013
    ....
  39. pmc Prognostic significance of ESR1 gene amplification, mRNA/protein expression and functional profiles in high-risk early breast cancer: a translational study of the Hellenic Cooperative Oncology Group (HeCOG)
    George Pentheroudakis
    Department of Medical Oncology, Ioannina University Hospital, Ioannina, Greece
    PLoS ONE 8:e70634. 2013
    ..Discrepant data have been published on the incidence and prognostic significance of ESR1 gene amplification in early breast cancer...
  40. ncbi request reprint Prognostic factors and significance of the revised 6th edition of the AJCC classification in patients with locally advanced nasopharyngeal carcinoma
    Anna Kalogera-Fountzila
    Department of Radiology, AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
    Strahlenther Onkol 182:458-66. 2006
    ....
  41. pmc DARPP32, STAT5 and STAT3 mRNA expression ratios in glioblastomas are associated with patient outcome
    Despina Televantou
    Department of Pathology, School of Medicine, Aristotle University of Thessaloniki, University Campus, 54006, Thessaloniki, Greece
    Pathol Oncol Res 19:329-43. 2013
    ..These data may contribute to understanding the biology of gliomas with respect to their potential neuronal characteristics and justify STAT-inhibiting therapeutic interventions in the same tumour system...
  42. ncbi request reprint Concomitant radiochemotherapy vs radiotherapy alone in patients with head and neck cancer: a Hellenic Cooperative Oncology Group Phase III Study
    George Fountzilas
    AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
    Med Oncol 21:95-107. 2004
    ..The present study clearly demonstrated that concomitant chemoradiotherapy with platinum analogs significantly prolongs 3-yr survival and median OS in patients with locally advanced HNC compared to conventional RT alone...
  43. doi request reprint Profiling immunohistochemical expression of NOTCH1-3, JAGGED1, cMET, and phospho-MAPK in 100 carcinomas of unknown primary
    Dimitrios Krikelis
    Department of Medical Oncology, Medical School, Aristotle University of Thessaloniki, Papageorgiou Hospital, Thessaloniki, Greece
    Clin Exp Metastasis 29:603-14. 2012
    ..001). Our study points to the MAPK and cMET axes as crucial in defining cancer progression and outcome in CUP patients and, if validated, could justify attempts at their therapeutic modulation...
  44. ncbi request reprint Irinotecan and oxaliplatin combination, as second-line treatment, in fluoropyrimidine-pretreated advanced colorectal cancer. A phase II study by the Hellenic Cooperative Oncology Group (HeCOG)
    Eleni Timotheadou
    Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece
    Tumori 91:309-13. 2005
    ..The management of patients with fluoropyrimidine-resistant advanced colorectal cancer remains Investigational. Irinotecan and oxaliplatin have proved effective in first-line treatment in combination with 5-fluorouracil...
  45. doi request reprint HLA Class II alleles and the presence of circulating Epstein-Barr virus DNA in Greek patients with nasopharyngeal carcinoma
    Charisios Karanikiotis
    424 Army General Hospital, Thessaloniki, Greece
    Strahlenther Onkol 184:325-31. 2008
    ....
  46. pmc Targeted KRAS mutation assessment on patient tumor histologic material in real time diagnostics
    Vassiliki Kotoula
    Department of Pathology, Papageorgiou Hospital, Aristotle University of Thessaloniki, School of Medicine, Thessaloniki, Greece
    PLoS ONE 4:e7746. 2009
    ..In routine diagnostics, however, suboptimal templates pose the challenge. Herein, we addressed the applicability of sequencing and two Q-PCR methods on prospectively assessed diagnostic cases for KRAS mutations...
  47. pmc MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer
    George Fountzilas
    Department of Medical Oncology, Papageorgiou Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece
    J Oncol 2009:305908. 2009
    ..However, this is a hypothesis generating study and the results should not be viewed as definitive evidence until they are validated in a larger cohort...
  48. pmc Insulin-like growth factor 1 receptor (IGF1R) expression and survival in operable squamous-cell laryngeal cancer
    Giannis Mountzios
    Department of Medical Oncology, 251 Airforce General Hospital, Athens, Greece
    PLoS ONE 8:e54048. 2013
    ..The insulin-like growth factor receptor (IGFR) signaling pathway plays a critical role in laryngeal carcinogenesis and progression...
  49. ncbi request reprint Paclitaxel and gemcitabine, as first-line chemotherapy, combined with trastuzumab in patients with advanced breast cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG)
    George Fountzilas
    1 st Department of Internal Medicine, Oncology Section, AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
    Cancer Invest 22:655-62. 2004
    ..This combination is the first to demonstrate a survival advantage in this group of patients. To improve on these results, we investigated a triplet, paclitaxel-gemcitabine-trastuzumab (TGH), in a phase II study...
  50. ncbi request reprint Evaluation of the prognostic value of HER-2 and VEGF in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy
    Ioannis Kostopoulos
    Aristotle University of Thessaloniki, School of Medicine, Thessaloniki, Greece
    Breast Cancer Res Treat 96:251-61. 2006
    ..To assess the prognostic and predictive significance of HER-2 overexpression and high expression of VEGF in high-risk patients with breast cancer treated with dose-dense sequential chemotherapy...
  51. pmc Expression profiling of 21 biomolecules in locally advanced nasopharyngeal carcinomas of Caucasian patients
    Dimitrios Krikelis
    Department of Medical Oncology Papageorgiou Hospital, Aristotle University of Thessaloniki School of Medicine, Ring Road of Thessaloniki, Nea Efkarpia, Thessaloniki, PC, 56403, Greece
    BMC Clin Pathol 13:1. 2013
    ..abstract:..
  52. ncbi request reprint Advances in the treatment of locally advanced non-nasopharyngeal squamous cell carcinoma of the head and neck region
    Amanda Psyrri
    Department of Medical Oncology, Papageorgiou Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece
    Med Oncol 23:1-15. 2006
    ..Cyclin-dependent kinases, the tumor suppressor p53 gene, and epidermal growth factor receptor are some of the molecular targets of such therapies in patients with SCCHN...
  53. pmc STAT-Related Profiles Are Associated with Patient Response to Targeted Treatments in Locally Advanced SCCHN
    Vassiliki Kotoula
    Department of Pathology, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece
    Transl Oncol 4:47-58. 2011
    ..The STAT5A/EPHA2 profile seems of particular interest for validation in larger cohorts and in multiple tumor types because markers for the positive selection of patients to benefit from CTX-containing treatments are currently lacking...
  54. ncbi request reprint Adjuvant cytotoxic and endocrine therapy in pre- and postmenopausal patients with breast cancer and one to nine infiltrated nodes: five-year results of the Hellenic Cooperative Oncology Group randomized HE 10/92 study
    George Fountzilas
    1st Department of Internal Medicine, AHEPA Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki Macedonia, Greece
    Am J Clin Oncol 27:57-67. 2004
    ..Similarly, six cycles of CNF preceding 5 years of tamoxifen did not translate to a 15% RFS benefit in node-positive postmenopausal patients...
  55. ncbi request reprint Elderly patients with squamous lung carcinoma: faring better or worse?
    George Pentheroudakis
    Department of Medical Oncology, Ioannina University Hospital, 45500 Ioannina, Greece
    Support Care Cancer 14:867-70. 2006
    ..The clinical course, management, and outcome of squamous lung cancer in the elderly have not been thoroughly studied to date...
  56. pmc Transcriptional activity of human epidermal growth factor receptor family and angiogenesis effectors in locoregionally recurrent head and neck squamous cell carcinoma and correlation with patient outcome
    George Pentheroudakis
    Department of Medical Oncology, Ioannina University Hospital, Ioannina 45500, Greece
    J Oncol 2009:854127. 2009
    ..Active transcription of the VEGF-C/VEGFR3 axis in recurrent HNSCC is associated with failure at neck soft tissues/lymph nodes and inferior survival post-relapse...
  57. ncbi request reprint Clinical and molecular prognostic factors in operable laryngeal cancer
    Konstantinos Vlachtsis
    Department of Otorhinolaryngology Head and Neck Surgery, AHEPA Hospital, Aristotle University of Thessaloniki, Greece
    Eur Arch Otorhinolaryngol 262:890-8. 2005
    ..These markers, apart from their role in carcinogenesis, seem to play an important role in tumor relapse...
  58. ncbi request reprint Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group
    George Fountzilas
    AHEPA Hospital, School of Medicine, Aristotle University of Thessaloniki, Nea Efkarpia, 56249 Thessaloniki, Greece
    Breast Cancer Res Treat 92:1-9. 2005
    ..7 and 42.7%, respectively), with the majority (72.1%) negative for cytoplasmic p27(kipl). The observed efficacy data in this study were similar to those reported for the combination of paclitaxel and carboplatin alone...
  59. ncbi request reprint Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group
    George Fountzilas
    1st Department of Internal Medicine, Oncology Section, AHEPA Hospital, Aristotle University of Thessaloniki, Greece
    Clin Breast Cancer 4:120-5. 2003
    ..9+). In conclusion, this retrospective analysis suggests that continuation of trastuzumab beyond disease progression in patients with HER2-overexpressing metastatic breast cancer is feasible and safe. Randomized studies are warranted...
  60. ncbi request reprint A novel chromatographic method for Ep-CAM mRNA detection in peripheral blood and bone marrow of patients with metastatic colorectal cancer
    Charisios Karanikiotis
    Department of Medical Oncology, 424 Army General Hospital, Thessaloniki, Greece
    Anticancer Res 25:319-23. 2005
    ....
  61. ncbi request reprint Technology evaluation: TriGem, Titan
    Evangelia Razis
    First Department of Internal Medicine, Aristotle University of Thessaloniki Medical School, Thessaloniki, Macedonia, Greece
    Curr Opin Mol Ther 5:204-7. 2003
    ..Phase II trials of TriGem for use in advanced melanoma were ongoing by June 2002. TriGem also has potential for the treatment of psoriasis, for which phase II trials had begun by 1996...